Regeneron enters venture investing with $500M, poaches senior partner from ARCH
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena.
The New York pharma will commit $100 million per …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.